1. The FDA announced new measures aimed at bringing generic drugs to market more quickly. The agency will issue new draft guidance for companies submitting generic applications for complex drugs. (FDA)
2. Allergan CEO Brent Saunders responded to criticism of his company’s patent deal with the Saint Regis Mohawk Tribe for eye drug Restasis. Saunders wrote in a letter to the Senate Judiciary Committee that regardless of the patent transfer, Restasis will still face patent challenges. (CNBC)
3. The death rate for breast cancer dropped nearly 40% between 1989 and 2015, according to a new report from the American Cancer Society. The report said new treatments and early detection are behind the decline. (WaPo)
4. A poll of 1,000 U.S. adults found that almost all, or 92%, said they would listen to a pharmacist’s recommendations on health advice or education on social media. (Chain Drug Review)
5. ICYMI: Eli Lilly named a new CFO and head of R&D, Josh Smiley and Dan Skovronsky, respectively. Smiley will take over as CFO in January while Skovronsky will become president of R&D on June 1. (CNBC)
